Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $15.0400 (-3.16%) ($15.0100 - $16.1300) on Mon. Jul. 13, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.26% (three month average) | RSI | 48 | Latest Price | $15.0400(-3.16%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.8% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.8% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(51%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -2.13% in a week (0% probabilities). VIXM(-28%) VXX(-14%) UUP(-12%) IYT(-5%) XLC(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.13% (StdDev 4.26%) | Hourly BBV | 0 () | Intraday Trend | -4.3% | | | |
|
5 Day Moving Average | $15.61(-3.65%) | 10 Day Moving Average | $15.54(-3.22%) | 20 Day Moving Average | $14.99(0.33%) | To recent high | -5.3% | To recent low | 50% | Market Cap | $3.884b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |